$WHG

The Texas Stock Exchange Has Its First New ETF. Its Power Bet Also Sells Calls

Westwood Holdings Group (WHG) launched the Westwood Salient Enhanced Power & Infrastructure ETF (PWRX) on the Texas Stock Exchange, the first new ETF on the venue. The fund targets income and capital appreciation in the energy sector using covered calls. WHG's Houston-based team manages the fund, which invests across the power ecosystem. PWRX joins WHG's Enhanced Income Series.

Original reporting
Published Oct 13, 2026, 10:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Texas Stock Exchange Has Its First New ETF. Its Power Bet Also Sells Calls — source image
Decision brief

The 30-second read

$WHGNeutralLow
01

Why it matters

The launch signals confidence in the venue and may encourage other issuers to consider Texas for new products, though investor uptake remains uncertain.

02

Market read

A niche product launch with modest immediate market impact, primarily relevant to investors in energy‑infrastructure ETFs and to the Texas exchange ecosystem.

03

What to watch

Potential counterparty and MLP risks, and the nascent liquidity of the Texas Stock Exchange, could affect performance.

Relevance 5/10Novelty 5/10Timing: immediate release

Background

The Texas Stock Exchange recently attracted several funds moving primary listings, but this is its first brand‑new ETF launch.

Company-level read

Ticker impact

$WHGNeutralHigh confidence
Context

Westwood Holdings Group announced the launch of the Westwood Salient Enhanced Power & Infrastructure ETF (PWRX) on the Texas Stock Exchange, the first new ETF on that venue.

Expected impact

likely modest pressure as investors assess the income‑focused structure and venue novelty

Evidence & confidence

The fund is newly launched with limited history; its impact will depend on investor appetite for covered‑call income strategies and the adoption of the Texas Stock Exchange.

Market effects

May highlight growing interest in power‑infrastructure exposure and covered‑call ETFs within the broader energy/infrastructure sector.

Could boost visibility of the Texas Stock Exchange as a venue for new fund listings.

Limited; primarily a US‑focused product with niche investor appeal.

Counterpoint

Investors might avoid the ETF due to capped upside from the call overlay, preferring pure equity exposure to the power sector.

Key entities

  • Westwood Holdings Group

    Dallas‑based firm launching the new ETF.

  • Texas Stock Exchange

    Venue hosting its first new ETF.

Related articles

$WHGMed

Westwood Holdings (WHG) Q2 2026 Earnings Call Transcript

Westwood Holdings Group (WHG) reported Q2 2026 revenues of $25.3 million and net income of $1.5 million, or $0.17 per diluted share. Economic earnings were $3.0 million, or $0.33 per share. Assets under management were $17.0 billion after $1.6 billion net outflows. The firm said its ETF, private capital, and managed solutions segments each exceed $500 million and noted the PWRX ETF will list mid-September on the Texas Stock Exchange.

$WHGMed

Westwood Holdings Group, Inc. Reports Second Quarter 2026 Results

WESTWOOD HOLDINGS GROUP INC (WHG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Westwood Holdings Group, Inc. Reports Second Quarter 2026 Results Private Capital platform surpassed $500 million in assets Managed Investment Solutions flows reached $350 million Dallas, TX, August 6, 2026 – Westwood Holdings Group, Inc. (NYSE: WHG) today reported second quarter

$CMPXMedAI 8/10

Compass Therapeutics publishes tovecimig trial results in JCO

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.